Cite

    Zheng, S. et al. (2023). Dissecting the role of cancer‐associated fibroblast‐derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single‐cell transcriptomic study. Clinical and translational medicine. 13 (2), p. n/a. [Online].